GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (NAS:WVE) » Definitions » Enterprise Value

WAVE Life Sciences (WAVE Life Sciences) Enterprise Value : $401.6 Mil (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is WAVE Life Sciences Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, WAVE Life Sciences's Enterprise Value is $401.6 Mil. WAVE Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-68.0 Mil. Therefore, WAVE Life Sciences's EV-to-EBIT ratio for today is -5.91.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, WAVE Life Sciences's Enterprise Value is $401.6 Mil. WAVE Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-58.8 Mil. Therefore, WAVE Life Sciences's EV-to-EBITDA ratio for today is -6.83.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, WAVE Life Sciences's Enterprise Value is $401.6 Mil. WAVE Life Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $113.3 Mil. Therefore, WAVE Life Sciences's EV-to-Revenue ratio for today is 3.54.


WAVE Life Sciences Enterprise Value Historical Data

The historical data trend for WAVE Life Sciences's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences Enterprise Value Chart

WAVE Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 160.80 228.70 67.25 557.59 433.54

WAVE Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 557.59 253.84 220.97 463.04 433.54

Competitive Comparison of WAVE Life Sciences's Enterprise Value

For the Biotechnology subindustry, WAVE Life Sciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WAVE Life Sciences's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Enterprise Value distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's Enterprise Value falls into.



WAVE Life Sciences Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

WAVE Life Sciences's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

WAVE Life Sciences's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WAVE Life Sciences  (NAS:WVE) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

WAVE Life Sciences's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=401.611/-67.996
=-5.91

WAVE Life Sciences's current Enterprise Value is $401.6 Mil.
WAVE Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-68.0 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

WAVE Life Sciences's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=401.611/-58.79
=-6.83

WAVE Life Sciences's current Enterprise Value is $401.6 Mil.
WAVE Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.8 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

WAVE Life Sciences's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=401.611/113.305
=3.54

WAVE Life Sciences's current Enterprise Value is $401.6 Mil.
WAVE Life Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $113.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WAVE Life Sciences Enterprise Value Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


WAVE Life Sciences (WAVE Life Sciences) Business Description

Traded in Other Exchanges
Address
Marina One East Tower, 7 Straits View No. 12-00, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.
Executives
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kyle Moran officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chris Francis officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chandra Vargeese officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Paul Bolno director, officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A. Panzara officer: Franchise Lead, Neurology 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Aik Na Tan director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
David G Gaiero officer: Interim CFO 733 CONCORD AVENUE, C/O WAVE LIFE SCIENCES USA, INC., CAMBRIDGE MA 02138
Gregory L. Verdine director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Heidi L Wagner director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Amy Pott director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Mark Corrigan director